Table 4.
Outcome | Independent variable |
Hazard ratio | 95% CI | |
---|---|---|---|---|
Legal blindness (diencephalon tumors only, n = 97) | Age at diagnosis | <5 yrs | 1.0 | 0.4–3.0 |
≥5 yrs | 1.0 | |||
Era | 1985–1996 | 3.3 | 1.3–8.5 | |
1997–2007 | 1.0 | |||
Chemo | Yes | 1.2 | 0.4–3.3 | |
No | 1.0 | |||
Tumor location | Hypothalamic/chiasmatic | 11.0 | 1.6–75.9 | |
Thalamic/other | 1.0 | |||
Hearing abnormal | Age at diagnosis | <5 yrs | 1.7 | 0.9–3.5 |
≥5 yrs | 1.0 | |||
Surgery | GTR | 0.7 | 0.3–1.7 | |
<GTR | 1.0 | |||
RT | Yes | 3.4 | 1.2–9.5 | |
No | 1.0 | |||
Tumor location | Brainstem | 2.2 | 1.1–4.9 | |
Other | 1.0 | |||
Field deficit | Chemo | Yes | 0.9 | 0.5–1.5 |
No | 1.0 | |||
RT | Yes | 1.3 | 0.8–2.3 | |
No | 1.0 | |||
Surgery | GTR | 0.8 | 0.4–1.6 | |
<GTR | 1.0 | |||
Tumor location | Supratentorial | 9.3 | 3.7–23.7 | |
Infratentorial | 1.0 | |||
Era | 1985–1996 | 0.7 | 0.4–1.2 | |
1997–2007 | 1.0 | |||
NF-1 | Yes | 1.2 | 0.7–2.2 | |
No | 1.0 | |||
Growth hormone deficiency | Chemo | Yes | 0.8 | 0.4–1.4 |
No | 1.0 | |||
RT | Yes | 3.9 | 1.9–8.2 | |
No | 1.0 | |||
Surgery | GTR | 0.2 | 0.1–0.6 | |
<GTR | 1.0 | |||
Tumor location | Diencephalon | 3.5 | 1.6–7.7 | |
Other | 1.0 | |||
NF-1 | Yes | 1.1 | 0.5–2.1 | |
No | 1.0 | |||
Hypothyroid | Sex | Male | 1.4 | 0.8–2.5 |
Female | 1.0 | |||
Chemo | Yes | 1.1 | 0.6–1.9 | |
No | 1.0 | |||
RT | Yes | 2.8 | 1.4–5.4 | |
No | 1.0 | |||
Surgery | GTR | 0.5 | 0.2–1.1 | |
<GTR | 1.0 | |||
Tumor location | Diencephalon | 4.0 | 2.0–8.2 | |
Other | 1.0 | |||
NF-1 | Yes | 0.7 | 0.3–1.4 | |
No | 1.0 | |||
ACTH deficiency | Sex | Male | 1.6 | 0.9–3.0 |
Female | 1.0 | |||
Chemo | Yes | 0.8 | 0.4–1.5 | |
No | 1.0 | |||
RT | Yes | 4.6 | 2.1–10.0 | |
No | 1.0 | |||
Surgery | GTR | 0.4 | 0.2–1.2 | |
<GTR | 1.0 | |||
Tumor location | Diencephalon | 3.4 | 1.6–7.3 | |
Other | 1.0 | |||
Era | 1985–1996 | 0.5 | 0.3–0.9 | |
1997–2007 | 1.0 | |||
Hyperinsulinism/insulin resistant | Race | White | 0.3 | 0.1–0.7 |
Other | 1.0 | |||
RT | Yes | 1.9 | 0.8–4.6 | |
No | 1.0 | |||
Surgery | GTR | 1.1 | 0.3–4.0 | |
<GTR | 1.0 | |||
Tumor location | Diencephalon | 2.0 | 0.6–6.1 | |
Other | 1.0 | |||
Era | 1985–1996 | 0.4 | 0.1–0.9 | |
1997–2007 | 1.0 | |||
Obese/overweight | Race | White | 0.6 | 0.3–0.9 |
Other | 1.0 | |||
RT | Yes | 1.3 | 0.8–2.0 | |
No | 1.0 | |||
Chemo | Yes | 1.0 | 0.6–1.5 | |
No | 1.0 | |||
Surgery | GTR | 0.7 | 0.4–1.2 | |
<GTR | 1.0 | |||
Tumor location | Diencephalon | 1.8 | 1.1–2.8 | |
Other | 1.0 | |||
Era | 1985–1996 | 0.7 | 0.5–1.1 | |
1997–2007 | 1.0 | |||
Epilepsy | Age at diagnosis | <5 yrs | 1.7 | 0.7–4.0 |
≥5 yrs | 1.0 | |||
RT | Yes | 1.3 | 0.5–3.2 | |
No | 1.0 | |||
Chemo | Yes | 1.0 | 0.4–2.7 | |
No | 1.0 | |||
Surgery | GTR | 0.8 | 0.3–2.2 | |
<GTR | 1.0 | |||
Tumor location | Supratent | 4.8 | 1.7–14.0 | |
Infratent | 1.0 | |||
Seizure | Chemo | Yes | 1.0 | 0.6–1.6 |
No | 1.0 | |||
Tumor location | Supratent | 3.7 | 2.0–7.0 | |
Infratent | 1.0 | |||
Headache | Age at diagnosis | <5 yrs | 0.7 | 0.4–1.1 |
≥5 yrs | 1.0 | |||
Sex | Male | 0.5 | 0.3–0.8 | |
Female | 1.0 | |||
RT | Yes | 0.7 | 0.4–1.0 | |
No | 1.0 | |||
Era | 1985–1996 | 0.5 | 0.3–0.8 | |
1997–2007 | 1.0 | |||
Cranial nerve deficit | Race | White | 0.6 | 0.3–1.2 |
Other | 1.0 | |||
Surgery | GTR | 0.5 | 0.2–0.9 | |
<GTR | 1.0 | |||
Tumor location | Supratent | 0.4 | 0.2–0.8 | |
Infratent | 1.0 |
GTR, gross total resection; ACTH, adrenocorticotropic hormone; NF-1, neurofibromatosis type 1.
Bold denotes covariates that are independantly statistically significant in the multivariate model.